Other Events ·
Nasdaq notifies Neumora Therapeutics of non-compliance with the $1.00 minimum bid price requirement
NMRANeumora Therapeutics, Inc.
Neumora Therapeutics received written notice from Nasdaq that its common stock is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market. The company has until April 26, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Failure to comply may result in delisting, though the company could apply to transfer to the Nasdaq Capital Market if it meets other listing standards. Neumora intends to monitor its stock price and consider options such as a reverse stock split to resolve the deficiency. The company operates in the biotechnology industry, focusing on drug discovery.